Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market. This story matters for Finance & Markets readers tracking currency. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. CurrencyNews curates and briefs the finance & markets stories that matter. Our editorial policy →